



Mithra Demonstrates Further Estetrol's Unique Profile at the Annual Meeting of the Endocrine Society

Liege, Belgium, 25 March 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health has presented the results of a new study on Estetrol (E4) at the 101st Annual Meeting of the Endocrine Society (ENDO 2019) held from March 23 to 26 in New Orleans (U.S.)

During the late breaking news session of this key international conference in endocrinology, Mithra presented the most recent findings on E4's mode of action. The results of this study delineate further E4's unique profile as an estrogen with selective actions in tissues, demonstrating the absence of specific membrane receptor effects.

This additional data strengthens E4's unique character and the innovation of the E4 research platform. The specificity of E4 activity with lower hepatic effects should ultimately translate into safer clinical use across a broad range of indications, starting with contraception, perimenopause and menopause.

Professor Jean-Michel Foidart, Perpetual Secretary of the Royal Academy of Medicine, commented: *"These results demonstrate further E4's specific profile and distinctive action from SERMs¹ on the ER α receptor. Previous studies have shown that E4 can activate estrogen receptors in some tissues, while in other tissues it acts as an anti-estrogen due to its ability to activate the nuclear estrogen receptor and block the membrane receptor²⁻³. This additional evidence complete distinctive E4 profile, differentiating it from current estrogens and also from other product families like SERMs which show a modular activity on estrogen receptors. The absence of specific membrane receptor effects and no interaction with ER α in the way of SERMs demonstrate E4's unique profile and shed a new light on E4's improved benefit/risk profile for the clinic."*

The abstract of this presentation entitled "Estetrol (E4), a unique estrogen with a selective mode of action on tissues different from that of SERMs" is available [here](#).

¹ Specific Estrogen-Receptor Modulators (SERM)

² Abot A., C Fontaine, M. Buscato, R Solinhac, G Flouriot, A Fabre, A Drougard, S Rajan, M Laine, A Milon, I Muller, D Henrion, M Adlanmerini, MC Valéra, A Gompel, C Gerard, C Pequeux, M Mestdagt, I Raymond-Letron, C Knauf, F Ferriere, P Valet, P Gourdy, B Katzenellenbogen, F Lenfant, G Greene, JM Foidart, JF Arnal (2014). "The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation." *EMBO Molecular Medicine* 6 (10): 1328-1346. Read more

³ Adlanmerini M., R Solinhac, A Abot, A Fabre, I Raymond-Letron, A Guihot, F Boudou, L Sautier, E Vessières, Q Hoon Kim, P Lière, C Fontaine, A Krust, JA Katzenellenbogen, P Gourdy, PW Shaul, D Henrion, JF Arnal, F Lenfant (2014). "Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions" *PNAS* 111 (2): E283-E290.

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra's unique native estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list on investors.mithra.com